Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S./EU Filings Position Bayer Compound As First Approval For CTEPH

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bayer has filed riociguat, a first-in-class oral soluble guanylate cyclase stimulator, in the U.S. and Europe for approval in both pulmonary arterial hypertension and a related condition, persistent/recurrent chronic thromboembolic pulmonary hypertension. The compound stands to become the first drug therapy approved for CTEPH.

Advertisement

Related Content

FDA Panel Endorses Riociguat For CTEPH Amid Worries It Will Displace Surgery
FDA Review Of Bayer’s Riociguat Suggests It’s All About The Dose
Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
Actelion And Bayer Hope Novel Drugs Can Take Over The Pulmonary Hypertension Market
Street Unsurprised By CRL For Oral Treprostinil, But United Therapeutics’ Stock Tumbles Anyway
PAH Market Snapshot: Actelion’s Tracleer Faces Stiffer U.S. Competition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel